The Kansas Medical Assistance Program (KMAP) has created a preferred drug list (PDL) to promote clinically appropriate utilization of pharmaceuticals in a cost-effective manner without compromising the quality of care. The Kansas Medicaid PDL was authorized by . 39-7,121a, allowing KMAP to develop a PDL based on safety, effectiveness and clinical outcomes. If these factors indicate no therapeutic advantage among the drugs being considered in the same drug class, then KMAP considers the net economic impact (lowest net cost to the State) of such drugs when recommending drugs for inclusion in the Medicaid PDL. The statute states that "drugs which do not have a significant, clinically meaningful therapeutic advantage in terms of safety, effectiveness or clinical outcomes may be excluded from the preferred drug formulary and be subject to prior authorization in accordance with state and federal laws."